Relay Therapeutics, Inc.
RLAY
Positions held
Your positionsRLAY isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Relay Therapeutics is positioned in a competitive biotechnology sector with a strong buy recommendation, indicating investor confidence in its future growth potential.
- The company's target mean price is $27.58, suggesting significant upside from current levels.
- Despite recent revenue declines, Relay's market cap stands at approximately $4.1 billion, reflecting its substantial valuation in the biotech space.
- Relay Therapeutics faces challenges with a negative operating margin of -25949.7% in the latest quarter, indicating severe financial strain.
- Revenue dropped by 88% compared to the prior quarter, falling from $3.0M to $0.3M.
- The company has a high debt-to-equity ratio of 3.445, raising concerns about its financial stability.
Fundamentals
| Market cap | $3.82B | Enterprise value | $2.93B | Trailing P/E | — | Forward P/E | -10.67 |
| PEG | — | Price / book | 4.27 | Beta | 1.73 | Dividend yield | 0.00% |
| Revenue growth | -48.3% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -259.5% |
| Profit margin | 0.0% | ROE | -36.8% | ROA | -22.9% | Debt / equity | 0.03 |
| Current ratio | 18.27 | Free cash flow | -$119.24M | Analyst recommendation | strong_buy | Mean target | $27.58 |
| 52w high | $21.27 | 52w low | $5.85 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.3M | $3.0M | $7.0M | $0.0M | $0.7M | — |
| Op margin | -25949.7% | -2619.7% | -866.1% | — | -11351.1% | — |
| Net income | -$83.7M | -$73.3M | -$54.9M | -$74.1M | -$70.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$90.8M | -$78.6M | -$60.6M | -$80.4M | -$76.8M | — |
- Revenue -88% vs prior quarter ($0.3M vs $3.0M).
- Operating margin compressed to -25949.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $15.4M | $10.0M | $25.5M | $1.4M | — |
| Op margin | -1971.6% | -3854.0% | -1485.3% | -22516.4% | — |
| Net income | -$276M | -$338M | -$342M | -$291M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$303M | -$386M | -$379M | -$311M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · What Could Go Wrong With Recursion Pharmaceuticals Stock?
2026-10-08 · Relay Therapeutics Insider Sold Shares Worth $872,402, According to a Recent SEC Filing
2026-10-08 · Relay Therapeutics Insider Sold Shares Worth $329,322, According to a Recent SEC Filing
2026-10-08 · Relay Therapeutics (RLAY) Stock Looks Fully Priced On Book Value
2026-10-08 · Is Relay Therapeutics (RLAY) Cheap After Its Pullback Or Is The Upside Priced In?
2026-10-01 · Raymond James Updates Healthcare Top Picks for October
2026-09-24 · Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
2026-09-22 · X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
2026-09-09 · Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing
2026-09-03 · Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
2026-09-02 · Relay Therapeutics CFO Sells 17,717 Shares for $350,000
2026-09-01 · Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Price (daily)
Full chart · RSI · MACD · patterns